ARID1A and ovarian carcinoma: Indeed, the BAF components ARID1A and SMARCA2/4 are persistently mutated in ovarian cancer subtypes,64, 65, 66, 67 and represent promising sensitivities for epigenetic inhibition therapy, as discussed below.